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Available online at www.sciencedirect.comFaecal microbiota transplantation (FMT) has been used for
more than five decades to treat a variety of intestinal diseases
associated with pathological imbalances within the resident
microbiota, termed dysbiosis. FMT has been particularly
effective for treating patients with recurrent Clostridium difficile
infection who are left with few clinical options other than
continued antibiotic therapy. Our increasing knowledge of the
structure and function of the human intestinal microbiota and C.
difficile pathogenesis has led to the understanding that FMT
promotes intestinal ecological restoration and highlights the
microbiota as a viable therapeutic target. However, the use of
undefined faecal samples creates a barrier for widespread
clinical use because of safety and aesthetic issues. An
emerging concept of bacteriotherapy, the therapeutic use of a
defined mixture of harmless, health-associated bacteria, holds
promise for the treatment of patients with severe C. difficile
infection, and possibly represents a paradigm shift for the
treatment of diseases linked to intestinal dysbiosis.
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Introduction
The human intestine is inhabited by a diverse and
abundant community of microorganisms, collectively
termed the intestinal microbiota, that plays crucial roles
in our development and sustenance [1]. Proper function-
ing and homeostasis of our intestine relies on an intimate
and symbiotic relationship between our mucosal surface,
the microbiota and its metabolic by-products. Homeosta-
sis is characterized by a diverse microbiota that produces a
variety of metabolites such as short-chain fatty acids
Open access under CC BY license.Current Opinion in Microbiology 2013, 16:596–601 (SCFAs), and this is coupled to a lack of pathology
associated with specific T-cell subsets [2].
Pathological imbalances in the intestinal microbiota,
referred to as dysbiosis, are increasingly linked to intes-
tinal diseases. Disturbances in the intestinal microbiota
caused by infections and antibiotics have profound effect
on the microbiota’s composition and function and can
predispose the individual to antibiotic-associated diar-
rhoea (AAD). In the last decade, the incidence of mor-
bidity and mortality from Clostridium difficile infection
(CDI), the leading cause of AAD, increased largely due
to the emergence and global spread of fluoroquinolone-
resistant variant of C. difficile (characterized as genotype
BI/NAPI/027) [3]. C. difficile is continuously evolving in
response to antibiotic selection and other ribotypes (such
as 017 and 078) have also been identified in humans and
animal sources that could also spread globally [4,5]. First
line treatment for severe C. difficile infections include
metronidazole or vancomycin although in 15–35% of
these cases, a recurrence (relapse or reinfection) follows
the cessation of antibiotic therapy.
Faecal microbiota transplantation (FMT) has been
mainly used as an alternative treatment for patients with
persistent, recurrent C. difficile infection and involves the
restoration of the intestinal microbiota through instilla-
tion or engraftment of homogenized faecal suspension
from a healthy donor [6]. FMT has also been utilized in
the treatment of diseases associated with intestinal dys-
biosis such as inflammatory bowel diseases (IBD; mani-
fested as Crohn’s disease and ulcerative colitis), irritable
bowel syndrome (IBS) and obesity [6]. This review
focuses on the use of FMT for the treatment of recurrent
CDI, the potential for designing a mixture of ‘harmless’
bacteria for the treatment of CDI infection and appli-
cations to other diseases. We refer to this clinical appli-
cation as ‘Bacteriotherapy’.
The human intestinal microbiota in health and
disease
The human intestinal microbiota contains >1000 bacterial
species, as well as other understudied organisms like
Archaea, eukaryotic organisms and viruses, that collec-
tively encode 150 times more unique genes than the
human genome [7,8,9]. Intestinal bacteria consist mainly
of strict anaerobes (>99%) and are involved in a variety of
functions beneficial to the host, including immunological
development and stimulation, SCFA production from the
breakdown of dietary fibre, conversion of xenobiotics towww.sciencedirect.com
Bacteriotherapy for the treatment of CDI Adamu and Lawley 597
Figure 1
(a) intestinal homeostasis
(b) antibiotic disruption
(c) transient dysbiosis
(d) increase in commensals
(e)  persistent dysbiosis
 exposure to C. difficile (g) resolution of C. difficile  
Bacteriotherapy
(f) disrupting dysbiosis  antibiotic treatment
 recurrence of CDI
Current Opinion in Microbiology
A proposed model for recurrent C. difficile infection and the restoration of the intestinal microbiota through FMT or bacteriotherapy. Intestinal
homeostasis (a) is characterized by large microbial diversity in the microbiota and health-associated metabolites. Antibiotic exposure disrupts the
microbiota (b–c) by destroying the microbial community leading to reduction in the diversity and loss of colonization resistance. The microbiota usually
expands in diversity (d) after antibiotics are stopped to restore diversity. Antibiotic disruption makes individuals hyper-susceptible to C. difficile
colonization potentially leading to chronic infection and persistent dysbiosis (e). After treatment of CDI with antibiotics such as vancomycin, further
microbiota disruption (f) occurs potentially leading to recurrent CDI after discontinued use of the antibiotic. FMT or bacteriotherapy disrupts intestinal
dysbiosis leading to resolution of CDI (g) and increase in species diversity (d) and restores intestinal homeostasis.
Figure modified from [48].less harmful substances, maintaining intestinal epithelial
integrity and generation of nutrients and vitamins [10,11].
An important function of our microbiota is colonization
resistance, through acting as a barrier against pathogen
colonization or overgrowth of resident opportunistic bac-
teria present at low levels [2,10,12]. These processes are
made possible due to the presence of abundant and
diverse microorganisms competing with an invading bac-
terium directly for niches and nutrients or through pro-
duction of antibacterial products like bacteriocins [2]
(Figure 1). Other factors such as diet, hygiene, lifestyle,
host genetics and immune status influence the bacterial
groups present in the intestinal microbiota to promote
intestinal homeostasis and colonization resistance [13].
Various diseases have been associated with dysbiosis in the
intestinal microbiota such as AAD, IBD, IBS, asthma and
obesity [14–17]. In addition, certain pathogens, such as
Salmonella Typhimurium and Citrobacter rodentium, exploitwww.sciencedirect.com intestinal inflammation to subvert colonization resistance
in mice [18,19]. Inflammation of the intestinal mucosa
caused by enteric pathogens leads to dysbiosis and a
decrease in the species diversity of the intestinal micro-
biota, allowing opportunistic pathogens to flourish at the
expense of the commensal or beneficial microbes [7].
Effects of antibiotics on the intestinal
microbiota
Numerous studies in humans and animals have investi-
gated the effects of various antibiotic classes on the
intestinal microbiota [14,20]. Generally, antibiotics
deplete the overall organismal abundance and drastically
alter the composition leading to a number of metabolic
shifts such as decreased production of SCFAs due to
reduced carbohydrate fermentation [14,21,22]. After ces-
sation of antibiotic treatment, the microbiota typically
recovers in abundance and diversity but may not return to
the original community structure as some species may be
missing [20] (Figure 1).Current Opinion in Microbiology 2013, 16:596–601
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particular antibiotic used and the degree of resistance
within the community [14]. For example, vancomycin is
active against both commensal and pathogenic Gram-
positive bacteria leading to intestinal dysbiosis [23–26].
Antibiotic usage can also lead to an increase in antibiotic
resistant organisms such as vancomycin-resistant entero-
cocci, methicillin-resistant Staphylococcus aureus and trans-
fer of antibiotic resistance genes among the microbial
community [23,25,27]. The long-term consequence of
antibiotic exposure on host health is poorly understood.
However, during the short-term (days to weeks), the host
may become hyper-susceptible to certain infections and
antibiotic-associated diarrhoea.
Clostridium difficile diarrhoea
Antibiotic perturbation of the microbiota predisposes
the host to pathogen colonization and overgrowth and
potentially diarrhoeal disease caused by bacteria such as
Klebsiella oxytoca, Clostridium perfringens, pathogenic
Escherichia coli and C. difficile [28]. C. difficile, an anaerobic,
spore-forming Gram-positive bacterium, is the leading
cause of AAD in hospitalized patients [3,29]. The inci-
dence of CDI in the last decade has increased leading to a
public health burden with estimated economic costs of at
least $1.5 billion per year in the USA alone [30].
Major risk factors for CDI include prolonged antimicro-
bial use, exposure to a healthcare environment and
advanced age [29]. C. difficile produces 2 toxins encoded
by tcdA and tcdB (though some variants also produce a
third binary toxin) that are known to facilitate pathogen-
esis [31]. C. difficile colonization is associated with differ-
ent outcomes ranging from asymptomatic carriage, mild/
chronic diarrhoea, fulminant colitis to toxic megacolon
and even death [29,32] (Figure 1).
C. difficile produces highly resistant and transmissible
spores that can potentially persist in the gut of infected
individuals or contaminate skin or environmental sur-
faces. These spores are resistant to antibiotics and can
re-colonize and germinate after antibiotic therapy leading
to recurrent disease [29,33]. Asymptomatic carriers are
also a source of spores that can promote transmission and
persistence at both the hospital and global levels [5].
Standard treatments for CDI involve the use of antibiotics
such as metronidazole and vancomycin [34,35]. However,
15–35% of these patients usually experience recurrent
disease, leaving few treatment options [36] (Figure 1).
Many patients become dependent on vancomycin (oral,
tapered and/or pulsed) to maintain remission and this has
implications for the intestinal microbiota. Chang et al. used
16S rRNA gene clone libraries to analyse the faecal micro-
biota of 7 patients with initial and recurrent CDI [21]. This
study demonstrated that patients with recurrent CDI had
decreased proportional abundance of Bacteroidetes andCurrent Opinion in Microbiology 2013, 16:596–601 increased Proteobacteria and Verrucomicrobia [21]. How-
ever, a new antibiotic, fidaxomicin was found to have lower
rates of recurrence of C. difficile infection associated with
the non-epidemic strain compared to vancomycin, an
effect that is attributed to its lower activity against com-
mensal and beneficial gut microbes [26].
FMT for treatment of recurrent CDI
Because of the recent increase in the rates of recurrence
and severity from epidemic C. difficile strains, there has
been renewed interest in the use of FMT for the treat-
ment of recurrent CDI. In this process, homogenized
faeces from a healthy donor is infused through colono-
scopy, enema or nasogastrically to an individual with C.
difficile disease to restore the intestinal microbiota and
thereby eradicate CDI [37–39] (Figure 1). The donor,
usually a healthy individual/relative, is screened for con-
tagious pathogenic agents such as Salmonella spp., Sta-
phylococcus aureus, C. difficile and HIV and other infections
or inflammatory conditions as previously described [32].
The intestinal microbiota of C. difficile patients treated with
FMT is characterized by expansions in species diversity
characterized by an increase in Bacteroides, Roseburia and
Faecalibacterium and a reduction in Enterobacteriaceae [40]
(Figure 1). Recently, Hamilton and co-workers analysed
the faecal microbiota of 3 patients treated by FMT using
frozen donor sample from the same individual and an
increase in Bacteroidetes and Firmicutes was observed
[41]. The Bacteroidetes were represented by greater abun-
dance of the families Bacteroidaceae, Rikenellaceae and Por-
phyromonadaceae and members of the Firmicutes were
represented by Lachnospiraceae, Ruminococcaceae and
unclassified Firmicutes [41]. These families are typically
found in abundant numbers in the intestines of healthy
individuals, suggesting that key groups of health-promot-
ing bacteria are associated with the displacement of CDI
and restoration of homeostasis in treated patients.
Several studies that employed FMT for the treatment of
recurrent CDI have reported success rates of 86–100%
[32,40–42]. van Nood and colleagues recently published
the first clinical trial to directly compare FMT with
vancomycin only or vancomycin with bowel lavage for
the treatment of recurrent CDI [43]. Remarkably, FMT
resolved 13 of the 16 cases (81%) after first infusion
compared to only 31% for vancomycin and 23% for
vancomycin with bowel lavage [43]. On second infu-
sion, 2 of the 3 failed cases had resolution of CDI leading
to an overall success rate of >90% in this trial [43]. The
success rates observed in these studies highlight the
importance of having a healthy and diverse intestinal
microbiota and should establish FMT as a viable clinical
option for diseases associated with intestinal dysbiosis.
Presently, there is no global standardized protocol for
FMT as the process is largely dependent on the centrewww.sciencedirect.com
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Generic model to create a standardized, defined bacteriotherapy mixture for treatment of patients with severe CDI. Culturing and genomic profiling of
faecal samples from healthy donors and CDI patients (a) could potentially identify candidate bacteria that can be tested in vivo for safety and efficacy.
Whole genome sequencing will define the bacteria and provide a basis to determine phylogenetic position within the microbiota community (b). Clinical
trials (c) will be required to test efficacy of bacteriotherapy mixture in diseased humans with severe CDI before widespread clinical use (d).performing the FMT. However, it is pertinent to note
that in 2011, the Faecal Microbiota Transplantation
Workgroup proposed standard guidelines for treatment
of CDI with FMT such as patient inclusion/exclusion
criteria, donor selection and screening, preparation and
administering of faecal samples [32].
Rational design of a defined bacteriotherapy
The use of undefined faecal samples for FMT creates a
barrier for widespread clinical use, mainly because of the
amount of time needed to prepare and screen donor
samples, patient safety issues, non-standardization of the
treatment procedure and general doctor and patient aver-
sion [6,44]. Therefore, there is an unmet clinical need to
design a combination of harmless, health associated bac-
teria as a viable therapeutic option (Figure 2). Over two
decades ago, Tvede and Rask-Madsen demonstrated that
simple mixtures of 10 bacteria isolated from healthy faecal
samples can resolve recurrent C. difficile as effectively as
whole faecal transplants [45]. More recently, a mixture of
33 bacterial species isolated from a healthy donor was used
to eradicate CDI in two patients [46] These studies have
pioneered the concept of ‘Bacteriotherapy’ in humans but
have yet to meet the scrutiny of regulatory agencies during
the development a pharmaceutical product [47].
Experimental studies are also providing insight into the
mechanisms of successful FMT. A recently developed
murine infection model for C. difficile used a mixture of 6
defined bacteria to cure mice infected with the epidemic
C. difficile 027 strain [48]. During the resolution of in-
fection, at least 4 out of 6 bacterial strains colonized the
mice post-transplant and many low level commensal
bacteria present during disease expanded to increasewww.sciencedirect.com the microbiota diversity during disease resolution [48].
Whole genome sequencing was used to establish the
phylogeny of these therapeutic bacteria within the
broader microbiota and also rule out the possibility that
they code for known virulence factors. An important
study, Reeves et al. have used novel culturing methods
to identify a single Lachnospiraceae strain that can suppress
C. difficile infection in mice [49]. Studies into the basic
mechanisms of C. difficile suppression should guide the
rational selection of candidate bacteria for bacteriother-
apy development (Figure 2).
Furthermore, it will be important to identify the microbial
differences between healthy individuals and patients
with severe C. difficile disease, as this could guide the
selection of the bacterial species from the healthy donors
(Figure 2). It may be necessary to conduct a retrospective
study to identify the shifts in the intestinal microbiota of
patients’ post-FMT from several studies that have been
published in order to identify what bacterial groups are
present after FMT. Though, it is worth noting that
personalized responses to FMT have been previously
observed [50] and this could be due to factors such as
diet, genetics and lifestyle that influence the microbiota
structure and function.
Emerging applications of bacteriotherapy
Bacteriotherapy has potential applications for other dis-
eases associated with intestinal dysbiosis such as IBD and
IBS. Borody and colleagues used FMT to treat 6 patients
with refractory ulcerative colitis and follow up at 1–13
years post-FMT showed no clinical evidence of ulcera-
tive colitis [51]. Similarly, Duplessis et al. utilized FMT to
treat a patient with severe Crohn’s disease complicatedCurrent Opinion in Microbiology 2013, 16:596–601
600 Antimicrobialsby refractory CDI [52]. Obesity is another condition that
could potentially benefit from FMT [17,53]. FMT from
lean to obese individuals led to increased insulin sensi-
tivity in the patients compared to the control group [54].
Conclusion
The diversity of the human intestinal microbiota is key to
a number of biological processes that ensure the well-
being of an individual. Alterations caused by long-term
antibiotic use and infections are detrimental to the host as
seen in CDI. FMT is increasingly being accepted as a
treatment for recurrent CDI, but large, randomized
double-blinded studies are needed. However, beyond
FMT, bacteriotherapy using standardized mixtures of
beneficial bacteria could potentially be used in the future
for the treatment of recurrent CDI and other diseases
associated with dysbiosis in the intestinal microbiota such
as IBD, IBS and obesity.
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